28,615 results match your criteria Granulocytopenia

Mortality-associated clinical risk factors in patients with febrile neutropenia: A retrospective study.

IJID Reg 2021 Dec 20;1:5-11. Epub 2021 Sep 20.

Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand.

Objectives: To determine the predictors for 30-day all-cause mortality in patients with febrile neutropenia (FN) and develop a prediction score.

Methods: The electronic medical records of patients undergoing chemotherapy with FN between 2018 and 2019 were reviewed. Multivariate logistic regression was performed to identify factors associated with 30-day all-cause mortality to develop a parsimonious model. Read More

View Article and Full-Text PDF
December 2021

Neutropenia in Patients With Clozapine-Treated Schizophrenia: An Effect of Clozapine or a Consequence of SARS-CoV-2 Infection? A Systematic Review.

Am J Ther 2022 Jun 24. Epub 2022 Jun 24.

Universitatea Transilvania, Braşov, Romania; and.

Background: Clozapine is the only approved antipsychotic for treatment-resistant schizophrenia. Despite its therapeutic benefits, it is still widely underused, mainly because of its potential to cause agranulocytosis and neutropenia. Prescribing clozapine in COVID-19-positive patients became more challenging because of this potential side effect. Read More

View Article and Full-Text PDF

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population.

J Manag Care Spec Pharm 2022 Jul;28(7):795-802

Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville.

It is unknown whether using pegfilgrastim biosimilars is cost saving in a real-world setting. To compare medical costs including pegfilgrastim drug costs and febrile neutropenia (FN) treatment and management costs between pegfilgrastim biosimilars (pegfilgrastim-jmdb, pegfilgrastim-cbqv) and originator users for primary prophylaxis of febrile neutropenia. A retrospective cohort study using 2019 IBM MarketScan Commercial and Medicare Supplemental databases was conducted in adult patients with cancer initiating myelosuppressive chemotherapy courses. Read More

View Article and Full-Text PDF

Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis.

Curr Oncol 2022 Jun 14;29(6):4245-4259. Epub 2022 Jun 14.

Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.

Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disease in adults. Despite durable responses and sustained remission rates to frontline therapy, CLL is still incurable within standard therapy and eventually relapses. Maintenance therapies aim to achieve deep remission. Read More

View Article and Full-Text PDF

[Neutropenic enterocolitis in the pediatric cancer patient].

Rev Chilena Infectol 2022 02;39(1):59-69

Hospital Clínico San Borja Arriarán, Chile.

Neutropenic enterocolitis (NEC) is a heterogeneous disease of the gastrointestinal tract with systemic response, that corresponds to a severe and life-threatening clinical condition in immunocompromised patients, especially in childhood cancer. The pathologic features are poorly understood, although its multifactorial cause of NEC is well established and it is associated with the cytotoxic effects of the chemotherapy agents used and recognized by the classic triad of fever, neutropenia, and abdominal pain, secondary to gastrointestinal injuries that alters mucosal permeability and helps intramural bacterial invasion. NEC is truly a clinical challenge that requires an early diagnosis and a multidisciplinary approach including basic laboratory and imagological tests in high complexity centers. Read More

View Article and Full-Text PDF
February 2022

[Risk of infection in cancer patients colonized by extended expectrum p-lactamases and carbapenem producing Enterobacteriaceae].

Rev Chilena Infectol 2022 02;39(1):20-28

Universidad tecnológica de Pereira, Pereira, Colombia.

Background: The prevalence of multi-resistant microorganisms is a public health problem that continues to grow globally. There is a population that is mainly susceptible to being colonized and subsequently infected, and these are cancer patients.

Aim: To identify the clinical and pathological characteristics of cancer patients and their relationship with infection with ESBL and CPE producing microorganisms. Read More

View Article and Full-Text PDF
February 2022

Hypogammaglobulinaemia and B cell lymphopaenia in Barth syndrome.

BMJ Case Rep 2022 Jun 22;15(6). Epub 2022 Jun 22.

Pediatrics, Umm Al-Qura University College of Medicine, Makkah, Saudi Arabia

Barth syndrome (BTHS) is an X linked recessive disorder caused by a mutation in the tafazzin (TAZ) gene classically associated with the triad of neutropaenia and cardiac and skeletal myopathies. Here we present a case of BTHS in a 2-month-old male patient found to have a novel variant of the TAZ gene (hemizygous c.639G>A) leading to early termination of the tafazzin protein (p. Read More

View Article and Full-Text PDF

GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients.

World J Surg Oncol 2022 Jun 22;20(1):212. Epub 2022 Jun 22.

Department of Medical Oncology, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou, People's Republic of China.

Background: The link between glutathione S-transferase P1 (GSTP1) c.313A > G polymorphism and chemotherapy-related adverse events remains controversial. The goal of this study was to assess how this variant affected the toxicity of anthracycline-/paclitaxel-based chemotherapy in patients with breast cancer. Read More

View Article and Full-Text PDF

Clinical Efficacy of PEG-IFN-2a and PEG-IFN-2b in the Treatment of Hepatitis B e Antigen-Positive Hepatitis B and Their Value in Improving Inflammatory Factors and Hemodynamics in Patients: A Comparative Study.

Oxid Med Cell Longev 2022 11;2022:3185320. Epub 2022 Jun 11.

Department of Gastroenterology, The Second Hospital of Shanxi Medical University, Taiyuan, 030001 Shanxi, China.

Objective: To compare the merits and demerits of PEG-IFN-2a and PEG-IFN-2b for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB).

Methods: Clinical files from eighty-four CHB patients admitted to the Second Hospital of Shanxi Medical University between January 2018 and January 2019 were retrospectively analyzed and assigned to two groups: group 2a treated with PEG-IFN-2a and group 2b treated with PEG-IFN-2b. The clinical efficacy was compared between the above two arms, and the liver function (ALT, AST, HA, LN, and IV-C), HBV-DNA, HBsAg, HBeAg, and inflammatory factors (IFs, IL-1, IL-6, IL-8, and TNF-) were tested at 12 weeks (T1), 24 weeks (T2), and 48 weeks (T3). Read More

View Article and Full-Text PDF

Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.

Pharmacogenomics J 2022 Jun 16. Epub 2022 Jun 16.

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Although clozapine is the most effective pharmacotherapy for treatment-resistant schizophrenia, it is under-utilized, and initiation is often delayed. One reason is the occurrence of a potentially fatal adverse reaction, clozapine-induced agranulocytosis (CIA). Identifying genetic variations contributing to CIA would help predict patient risk of developing CIA and personalize treatment. Read More

View Article and Full-Text PDF

Metagenomic shotgun sequencing of blood to identify bacteria and viruses in leukemic febrile neutropenia.

PLoS One 2022 16;17(6):e0269405. Epub 2022 Jun 16.

Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, United States of America.

Despite diagnostic advances in microbiology, the etiology of neutropenic fever remains elusive in most cases. In this study, we evaluated the utility of a metagenomic shotgun sequencing based assay for detection of bacteria and viruses in blood samples of patients with febrile neutropenia. We prospectively enrolled 20 acute leukemia patients and obtained blood from these patients at three time points: 1) anytime from onset of neutropenia until before development of neutropenic fever, 2) within 24 hours of onset of neutropenic fever, 3) 5-7 days after onset of neutropenic fever. Read More

View Article and Full-Text PDF

Clozapine Use in a Movement Disorder Clinic.

Clin Neuropharmacol 2022 Jun 11. Epub 2022 Jun 11.

Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI.

Background: Clozapine is an effective antipsychotic for Parkinson's disease (PD) that does not worsen motor function and can improve tremor. It is approved for PD psychosis in Europe and Australia.

Objective: The aim of this study was to report on the use of clozapine in a movement disorder clinic. Read More

View Article and Full-Text PDF

Validation of the FENCE Risk Groups for Prediction of Febrile Neutropenia With First-Cycle Chemotherapy.

JNCI Cancer Spectr 2022 May;6(3)

Department of Biostatistics, Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan.

Background: The FEbrile Neutropenia after ChEmotherapy (FENCE) score was developed to estimate the risk of febrile neutropenia (FN) at first cycle of chemotherapy but has not been externally validated. We aimed to validate the FENCE score based on its risk groups in patients treated at a comprehensive cancer center.

Methods: We conducted a retrospective study of treatment-naïve adult patients with solid tumors and diffuse large B-cell lymphoma who received first-cycle chemotherapy between January and November 2019. Read More

View Article and Full-Text PDF

[Analysis of Agranulocytosis Time and Its Influencing Factors in Patients with Hematological Malignancies Treated with rhIL-11 combined rhG-CSF].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2022 Jun;30(3):930-936

Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China.

Objective: To explore the intervention effect of recombinant human interleukin-11 (rhIL-11) and recombinant human granulocyte-colony stimulating factor (rhG-CSF) on the duration and severity of agranulocytosis in patients with hematological malignancies after chemotherapy, and to analyze the influencing factors.

Methods: The data of hematological malignancy patients treated with rhIL-11 and rhG-CSF after chemotherapy in the hematology department of The First Hospital of Lanzhou University from July 2017 to July 2020 were collected retrospectively. The duration and differences of agranulocytosis in differeent groups were compared by univariate analysis, and the influencing factors of agranulocytosis duration were further analyzed by multiple regression analysis. Read More

View Article and Full-Text PDF

[Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study].

Zhonghua Xue Ye Xue Za Zhi 2022 Apr;43(4):287-292

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, National Clinical Research Center for Blood Diseases, Tianjin 300020, China.

To evaluate the efficacy and toxicity profiles of idarubicin, cytarabine, and cyclophosphamide (IAC) in relapse/refractory acute myeloid leukemia (AML) . This study was a prospective, randomized controlled clinical trial with the registration number NCT02937662. The patients were randomly divided into two groups. Read More

View Article and Full-Text PDF

Large granular lymphocytic leukemia cured by allogeneic stem cell transplant: a case report.

J Med Case Rep 2022 Jun 8;16(1):227. Epub 2022 Jun 8.

Department of Internal Medicine, New York University Grossman School of Medicine, 240 East 38th street, 19th Floor, New York, NY, 10016, USA.

Background: Large granular lymphocytic leukemia is a rare lymphocytic neoplasm that can pose a treatment challenge in patients with severe neutropenia in whom conventional therapies fail. We report one of the first cases in which allogeneic stem cell therapy was used as treatment for large granular lymphocytic leukemia. We report and discuss the case of a 42-year-old white Caucasian female who, despite multiple therapies including methotrexate, cyclophosphamide, prednisone, cyclosporine, and pentostatin, continued to show severe neutropenia and recurrent infections. Read More

View Article and Full-Text PDF

Unmasking of Metamizole-Induced Liver Injury by Simultaneous Development of Characteristic Agranulocytosis.

Curr Drug Saf 2022 Jun 6. Epub 2022 Jun 6.

Department of Medicine B, Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital of Münster; Albert-Schweitzer-Campus 1, D-48149 Münster, Germany.

Background: Metamizole is one of the most used analgesic, antipyretic, and spasmolytic agents in many countries worldwide. While metamizole-induced agranulocytosis is an, albeit seldom, well-known adverse event, metamizole-associated drug-induced liver injury has been reported rarely in the literature and hence often remains unconsidered. Here, we present a unique case where metamizole-induced hepatotoxicity got unmasked by the simultaneous development of characteristic agranulocytosis. Read More

View Article and Full-Text PDF

Effect of concomitant use of G-CSF and myelosuppressive chemotherapy on bone marrow and peripheral granulocytes in a mouse model.

Med Oncol 2022 Jun 6;39(8):110. Epub 2022 Jun 6.

Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan.

Granulocyte-colony stimulating factor (G-CSF) stimulates bone marrow progenitor cell proliferation and enhances neutrophil production. Exogenous G-CSF administration is indicated for chemotherapy-induced neutropenia management. However, there is a paucity of basic research examining the effects of the concomitant use of G-CSF and chemotherapy on myeloid cells in vivo. Read More

View Article and Full-Text PDF

Invasive Pulmonary Aspergillosis in Children: A Case Report and Literature Review.

Am J Case Rep 2022 Jun 5;23:e935971. Epub 2022 Jun 5.

Department of Pediatric, Prince Sultan Military Medical City (PSMMC), Riyadh, Saudi Arabia.

BACKGROUND Invasive pulmonary aspergillosis (IPA) is the major cause of mortality and morbidity in immunocompromised patients with prolonged neutropenia and is associated with poor prognosis. Multiple factors are associated with an increased risk of invasive aspergillosis, including persistent neutropenia, impaired lymphocyte engraftment following bone marrow transplantation, cytomegalovirus disease, respiratory virus infection, cytotoxic chemotherapy, and Aspergillus colonization. Unfortunately, attempts at fungal isolation are often unsuccessful. Read More

View Article and Full-Text PDF

Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis.

PLoS One 2022 3;17(6):e0269368. Epub 2022 Jun 3.

Unidad de Revisiones Sistemáticas y Meta-análisis (URSIGET), Universidad San Ignacio de Loyola (USIL), Lima, Peru.

Introduction: We systematically assessed benefits and harms of tocilizumab (TCZ), which is an antibody blocking IL-6 receptors, in hospitalized COVID-19 patients.

Methods: Five electronic databases and two preprint webpages were searched until March 4, 2021. Randomized controlled trials (RCTs) and inverse probability treatment weighting (IPTW) cohorts assessing TCZ effects in hospitalized, COVID-19 adult patients were included. Read More

View Article and Full-Text PDF

Acute lymphocytic leukemia in a patient with long-term carbamazepine exposure: Acute lymphoblastic leukemia that develops in a patient who has been using carbamazepine for a long time.

J Oncol Pharm Pract 2022 Jun 3:10781552221105856. Epub 2022 Jun 3.

Department of Hematology, Faculty of Medicine in 52993Selcuk University, Konya, Turkey.

Introduction: Carbamazepine is an antiepileptic drug used in the treatment of epilepsy, trigeminal neuralgia, and bipolar disorder. Hematological effects that may develop with this anticonvulsant; agranulocytosis, thrombocytopenia, leukopenia, aplastic anemia, eosinophilia, or pancytopenia.

Case Report: In this article, we wanted to present a case diagnosed with acute lymphoblastic leukemia after long-term use of carbamazepine because of epilepsy. Read More

View Article and Full-Text PDF

A Novel Risk Predictive Scoring Model for Predicting Subsequent Infection After Carbapenem-Resistant Gram-Negative Bacteria Colonization in Hematological Malignancy Patients.

Front Oncol 2022 11;12:897479. Epub 2022 May 11.

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background: This study investigated the high-risk factors associated with the increased vulnerability for subsequent clinical CR-GNB infection in carbapenem-resistant Gram-negative bacteria (CR-GNB)-colonized hematological malignancy (HM) patients and built a statistical model to predict subsequent infection.

Method: All adult HM patients with positive rectoanal swabs culture for CR-GNB between January 2018 and June 2020 were prospectively followed to assess for any subsequent CR-GNB infections and to investigate the risk factors and clinical features of subsequent infection.

Results: A total of 392 HM patients were enrolled. Read More

View Article and Full-Text PDF

Hyper-IgE and Carcinoma in CADINS Disease.

Front Immunol 2022 16;13:878989. Epub 2022 May 16.

Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Background: Atopic dermatitis (AD) affects up to 25% of children and 10% of adults in Western countries. When severe or recurrent infections and exceedingly elevated serum IgE levels occur in AD patients, an inborn error of immunity (IEI) may be suspected. The International Union of Immunological Societies classification lists variants in different genes responsible for so-called Hyper-IgE syndromes. Read More

View Article and Full-Text PDF

Evans Syndrome: A Case Report.

JNMA J Nepal Med Assoc 2022 May 5;60(249):482-484. Epub 2022 May 5.

Department of Medical Hematology and Oncology, Birat Medical College and Teaching Hospital, Biratnagar, Morang, Nepal.

Evans syndrome is defined as the concomitant or sequential association of warm autoimmune hemolytic anaemia with immune thrombocytopenia, and less frequently autoimmune neutropenia. It is associated with non-cross-reacting auto-antibodies directed against antigens specific to red blood cells, platelets or neutrophils. Clinical symptoms could be related to hemolysis and thrombocytopenia. Read More

View Article and Full-Text PDF

Biallelic CLPB mutation associated with isolated neutropenia and 3-MGA-uria.

Pediatr Allergy Immunol 2022 05;33(5):e13782

Research Unit of Primary Immunodeficiencies, Immune and Infectious Diseases Division, Academic Department of Pediatrics (DPUO), Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

View Article and Full-Text PDF

Autoimmune Neutropenia Associated With HHV-6 Virus Infection: A Case Report.

Front Immunol 2022 9;13:880016. Epub 2022 May 9.

Department of Medicine E, The Chaim Sheba Medical Center, Ramat-Gan, Israel.

Background: Autoimmune neutropenia (AIN) is divided into primary and secondary forms. The former is more prevalent in children and is usually a self-limiting disease. Secondary AIN is more common in adults and often occurs in the setting of another autoimmune disorder or secondary to infections, malignancies or medications. Read More

View Article and Full-Text PDF

Clinical and Laboratory Findings of SARS-CoV-2 Infection in Children Younger than 6 Months Old: Neutropenia is More Common Not Lymphopenia.

J Trop Pediatr 2022 04;68(3)

Division of Infectious Disease, Department of Pediatrics, Medical School of Ege University, Izmir 35100, Turkey.

Background: Studies on age-related differences in clinical and laboratory features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are limited. We aimed to evaluate the demographic, clinical, laboratory findings of SARS-CoV-2 infection in children younger than 6 months old and compare them with older children.

Methods: A single-center retrospective study, including 209 confirmed SARS-CoV-2 infection cases, was conducted between 11 March 2020 and 1 September 2021. Read More

View Article and Full-Text PDF

Clinical Features and Risk Factors of Severe Pneumonia in Children With Acute Lymphoblastic Leukemia.

Front Pediatr 2022 6;10:813638. Epub 2022 May 6.

Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

Objective: This study aims to analyze the clinical characteristics of pediatric acute lymphoblastic leukemia (ALL) complicated by pneumonia and the risk factors of severe cases to preliminarily construct a prediction model for ALL complicated by severe pneumonia.

Methods: A retrospective analysis was carried out on the clinical data of children diagnosed with ALL complicated by pneumonia hospitalized at the Department of Pediatrics of the Affiliated Hospital of Southwest Medical University between January 2013 and December 2020. The risk factors of severe ALL complicated by pneumonia were investigated with logistic regression analysis, and the risk prediction model was constructed. Read More

View Article and Full-Text PDF

Generation, expansion, and drug treatment of hematopoietic progenitor cells derived from human iPSCs.

STAR Protoc 2022 Jun 14;3(2):101400. Epub 2022 May 14.

Department of Oncology, Hematology, Immunology, and Rheumatology, University Hospital Tuebingen, 72074 Tuebingen, Germany.

Severe congenital neutropenia (CN) is a pre-leukemic bone marrow failure syndrome that can progress to acute myeloid leukemia (CN/AML). Patient material to study leukemogenesis, especially hematopoietic progenitor cells (HPCs) is limited and hard to access. We have established a protocol for generation of HPCs from iPSCs followed by HPC expansion on Sl/Sl feeder cells expressing FLT3L. Read More

View Article and Full-Text PDF

Case Report: First Report of T-Cell Large Granular Lymphocytic Leukemia With NPL-DHX9 Gene Fusion Successfully Treated With Cladribine: Clinical Experience and Literature Review.

Front Oncol 2022 6;12:824393. Epub 2022 May 6.

Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.

Background: T-cell large granular lymphocytic leukemia (T-LGLL) is a rare lymphoproliferative disorder that starts in T cells and is usually indolent. Long-term use of immunosuppressants, combined with agranulocytosis, is a double-edged sword, as both can lead to serious infections, especially in patients with combined hematologic malignancies and immune defects.

Case Presentation: A 30-year-old female patient was admitted to the hospital because of agranulocytosis for five years, with chest tightness, fatigue, and fever for two days. Read More

View Article and Full-Text PDF